President Donald Trump announced on Monday that his administration has reached agreements with nine additional pharmaceutical companies to lower the prices of certain medicines. These "most-favored-nation" deals aim to synchronize U.S. launch prices for new drugs with those in other wealthy countries and offer deeper discounts to state Medicaid programs. The new participants include Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB, bringing the total number of companies in the program to 26.
The administration is incentivizing these voluntary agreements by offering participating companies exemptions from potential future tariffs. While the White House has highlighted the deals as a primary effort to address health care costs, the specific terms, including which drugs are covered and the exact scale of price reductions, have not been released to the public. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. stated he is willing to share details excluding trade secrets, but the agency has not yet done so.
Democratic lawmakers, including Sens. Elizabeth Warren (D-Mass.) and Ron Wyden (D-Ore.), have requested full disclosure of the agreements, questioning the impact on consumers without public documentation. Simultaneously, the pharmaceutical industry group PhRMA argued that individual pricing decisions differ fundamentally from government-mandated price settings. In a separate legal development on Monday, the U.S. Supreme Court ruled 5-4 to allow the continued construction of a new 90,000-square-foot White House ballroom, dismissing a lawsuit from the National Trust for Historic Preservation on the grounds that the organization lacked the legal right to sue.
The Medicare GLP-1 Bridge Program, a related temporary demonstration project, has already shown a measurable impact for a specific subset of the population. According to White House data, more than 500,000 seniors have used the program to obtain weight-loss medications for a $50 monthly co-pay since July. This has resulted in a reported $216 million in total savings for these seniors, while the federal government acts as the "primary payer," covering the remainder of the $245 monthly net price provided by drugmakers.
A person using these programs would notice a difference in their pharmacy bills or Medicaid coverage depending on whether their specific medication is included in the voluntary deals. However, advocacy groups like Public Citizen note that because these are voluntary agreements rather than codified law, companies could potentially withdraw from the arrangements in the future. President Trump has asked Congress to pass legislation to make these most-favored-nation prices permanent, but the proposal faces opposition within his own party and intensive lobbying from the pharmaceutical industry. Without congressional action, the longevity of these price levels remains tied to the current administration's pressure campaign.
What happens next: The administration continues to seek congressional support to codify these deals into law, though no vote date is set. The construction of the new White House ballroom will proceed following the Supreme Court's decision, which did not rule on the project's legality but ended the immediate legal block. Further updates from HHS regarding the public release of drug-pricing contract details are pending.